S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Admedus Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive AHZ News and Ratings via Email

Sign-up to receive the latest news and ratings for Admedus and its competitors with MarketBeat's FREE daily newsletter.

About Admedus

Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue products; and researches and develops regenerative medicine and immunotherapies. The company offers CardioCel, a bio-scaffold material to repair congenital heart deformities and other heart defects, as well as to reconstruct dysfunctional heart valves and valve leaflets; and CardioCel 3D that enables physicians access to an arch reconstruction solution with non-antigenic response and calcification resistance. It also provides VascuCel, a collagen scaffold used in cardiac repairs and reconstructions; ambIT infusion pumps for the delivery of medications and pain relief; arcomed infusion systems; and Eldor, a specialized fenestrated catheters for the infusion of local anesthetics into surgical sites for post-operative pain management. In addition, the company offers DOSI-FUSER, a portable elastomeric pump; and DOSI-PAIN, a wound catheter for postoperative continuous infusion. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Toowong, Australia.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales





Next Earnings Date
Not Optionable


Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Admedus (ASX:AHZ) Frequently Asked Questions

What stocks does MarketBeat like better than Admedus?

Wall Street analysts have given Admedus a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Admedus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Admedus' key executives?

Admedus' management team includes the following people:
  • Mr. Wayne G. Paterson, CEO, Pres, MD & Exec. Director (Age 53)
  • Mr. Matthew McDonnell, Chief Financial Officer
  • Mr. David St. Denis, Chief Operating Officer
  • Ms. Martha Engel, Gen. Counsel
  • Dr. Kiran Bhirangi, Chief Medical Officer

What is Admedus' stock symbol?

Admedus trades on the ASX under the ticker symbol "AHZ."

How much money does Admedus make?

Admedus has a market capitalization of $0.00.

What is Admedus' official website?

The official website for Admedus is www.admedus.com.

How can I contact Admedus?

The company can be reached via phone at 61 7 3152 3200.

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.